Literature DB >> 17723808

Sarcomatoid lung cancer (spindle/giant cells): an aggressive disease?

Nicolas Venissac1, Daniel Pop, Sandra Lassalle, Frederic Berthier, Paul Hofman, Jérôme Mouroux.   

Abstract

OBJECTIVE: We investigated the clinical, surgical, and pathologic features of sarcomatoid lung carcinomas with spindle/giant cells, giving special attention to the prognostic behavior of these rare tumors.
METHODS: Surgical specimens from 39 patients (29 men and 10 women; mean age, 61 years) were examined by means of light microscopy. Preoperative and postoperative data were collected, and survival was calculated by using the Kaplan-Meier method.
RESULTS: Nineteen patients were diagnosed with cancer preoperatively. Only one sarcomatoid tumor had been diagnosed. Presenting symptoms were noted in 85% of patients, and complete resection was achieved in 37 tumors. Postoperative pTNM staging: T2/T3/T4, 22/15/2; N0/N1/N2, 28/8/3; 15 stage IB, 14 stage IIB, 7 stage IIIA, 2 stage IIIB, and 1 stage IV. Histopathologic analysis revealed necrosis in 90% of the tumors (34 pleomorphic, 3 spindle cell, and 2 giant cell carcinomas). During follow-up (median, 24 months), 21 patients died of disease recurrence, and 3 died of postoperative complications. The 5-year survival rate (33%; median, 11 months) was negatively influenced by large tumors (7.5% survival for > or =7 cm vs 56% for <7 cm, P = .0026). The disease-free interval was significant for patients who relapsed (0% for disease-free interval <6 months vs 33% for disease-free interval > or =6 months, P = .0019).
CONCLUSIONS: A highly heterogeneous group, spindle/giant cell lung carcinomas tend to be symptomatic, peripheral, and necrotic. Preoperative diagnosis is difficult. Most patients in our study relapsed and died the first year after surgical intervention. Surgical intervention can permit long-term survival, but adjuvant therapy warrants consideration because of the aggressive nature of these tumors.

Entities:  

Mesh:

Year:  2007        PMID: 17723808     DOI: 10.1016/j.jtcvs.2007.05.031

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  26 in total

1.  Adult jejunojejunal intussusception caused by metastasized pleomorphic carcinoma of the lung: report of a case.

Authors:  Baomin Shi; Gereon Gaebelein; Bert Hildebrandt; Wilko Weichert; Matthias Glanemann
Journal:  Surg Today       Date:  2009-11-01       Impact factor: 2.549

2.  Immunohistochemical overexpression of platelet-derived growth factor receptor-beta (PDGFR-β) is associated with PDGFRB gene copy number gain in sarcomatoid non-small-cell lung cancer.

Authors:  Anne S Tsao; Wei Wei; Elisabetta Kuhn; Loreto Spencer; Luisa M Solis; Milind Suraokar; J Jack Lee; Waun Ki Hong; Ignacio I Wistuba
Journal:  Clin Lung Cancer       Date:  2011-05-17       Impact factor: 4.785

3.  A case of rapidly growing pulmonary carcinosarcoma.

Authors:  Shuichi Sato; Teruaki Koike; Yasushi Yamato; Katsuo Yoshiya; Nozomu Motono; Mariko Takeshige; Keiichi Homma; Naoya Koizumi; Akira Yokoyama; Hiroko Tsukada
Journal:  Int J Clin Oncol       Date:  2010-03-10       Impact factor: 3.402

4.  Epidermal growth factor receptor mutation heterogeneity analysis of pulmonary sarcomatoid carcinoma successfully treated with erlotinib: A case report.

Authors:  Fangwen Zou; Guiyuan Xie; Jin-An Ma; Dong-Ai Zhou; Y I Jiang; Jiao-Yun Zheng
Journal:  Oncol Lett       Date:  2015-03-18       Impact factor: 2.967

5.  An unusual case of peripartum pulmonary oedema.

Authors:  Yogesh N V Reddy; Varun Sundaram; Jonathan S Stamler
Journal:  BMJ Case Rep       Date:  2013-09-26

6.  Fine-needle aspiration cytology of pleomorphic carcinomas of the lung.

Authors:  Hee Seung Choi; Hyesil Seol; Il Yeong Heo; Chang Won Jung; Soo Youn Cho; Sunhoo Park; Jae Soo Koh; Seung-Sook Lee
Journal:  Korean J Pathol       Date:  2012-12-26

7.  Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1).

Authors:  Vamsidhar Velcheti; David L Rimm; Kurt A Schalper
Journal:  J Thorac Oncol       Date:  2013-06       Impact factor: 15.609

8.  Could spindle cell lung carcinoma be considered and treated as sarcoma, according to its clinical course, morphology, immunophenotype and genetic finding?

Authors:  Milica Kontic; Jelena Stojsic; Ruza Stevic; Vera Bunjevacki; Biljana Jekić; Valerija Dobricic
Journal:  Pathol Oncol Res       Date:  2012-08-26       Impact factor: 3.201

9.  Giant cell lung carcinoma in a man with acquired immunodeficiency syndrome.

Authors:  Takahide Kodama; Kunihiko Miyazaki; Hiroaki Satoh; Shigemi Hitomi; Morio Ohtsuka
Journal:  Med Oncol       Date:  2008-10-21       Impact factor: 3.064

10.  Validity of using immunohistochemistry to predict treatment outcome in patients with non-small cell lung cancer not otherwise specified.

Authors:  Takahiro Ota; Keisuke Kirita; Reiko Matsuzawa; Hibiki Udagawa; Shingo Matsumoto; Kiyotaka Yoh; Seiji Niho; Genichiro Ishii; Koichi Goto
Journal:  J Cancer Res Clin Oncol       Date:  2019-09-07       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.